Novartis Cuts 2031 Sales Growth Target to 5%

Novartis cut its mid-term sales growth target to the lower end of its previous range on Thursday, promising 5% annual growth at constant currencies through 2031 as it heads into the biggest patent-expiry year in its history.

Novartis now expects 5% annual sales growth at constant currencies through 2031 — the bottom of the range it guided to a year earlier — and its core operating income margin remains on track to return to 40% or more by 2029. The Swiss drugmaker set out the new 2026–2031 guidance at its annual Meet Novartis Management event in London on November 19, 2026. A year earlier the company had guided to 5%–6% growth through 2030, Reuters reported.

Novartis raises peak sales targets to hold its 5% line

The raised peak sales estimates for Kesimpta, Scemblix and Leqvio are what the company leaned on to justify its 5% constant-currency CAGR. Novartis lifted peak sales forecasts for three of its marketed medicines — Kesimpta now seen at $8 billion rather than $6 billion, Scemblix at $5 billion instead of $4 billion and Leqvio at $5 billion up from $4 billion.

That came after Rhapsido, also known as remibrutinib, was recently upgraded to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis, Yahoo Finance/Investing.com reported.

Drug Previous peak sales guidance New peak sales guidance
Kesimpta $6 billion $8 billion
Scemblix $4 billion $5 billion
Leqvio $4 billion $5 billion
Rhapsido (remibrutinib) — $8 billion (recent upgrade)

With those moves, Novartis now counts nine in-market assets with peak sales potential of $3–10 billion: Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma group (Zolgensma and Itvisma) and Fabhalta, according to the company’s announcement. Those figures cover existing indications plus expected future ones, Securities.io noted.

The raised targets still depend on further indication expansion, not current revenue.

Novartis Cuts 2031 Sales Growth Target to 5%
Photo: morningstar.com

Novartis plans to grow through its biggest patent cliff

2026 brings the largest loss-of-exclusivity impact in Novartis’s history, management said, with Entresto, Tasigna and Promacta the significant products affected. Generic competition to Entresto, the heart drug, is already weighing on profit.

Under the mid-term plan, in-market assets are expected to more than offset that generic erosion through 2031, with the probability-weighted pipeline providing potential upside on top, Securities.io reported.

“As a pure-play innovative medicines company, Novartis has a strong track record of sales growth and core margin expansion, and in 2026 we expect to grow through the largest loss-of-exclusivity impact in our history,” said Vas Narasimhan.

Most of the nine highlighted assets hold US patent protection through the 2030s, per the company’s presentation. The exception is Cosentyx, whose US and EU composition-of-matter patents expire in 2029 and 2030 respectively — the same decade in which Reuters notes Novartis must show it can keep growing without another top seller.

Investors want proof the plan survives 2030

Reuters put the guidance in a sharper context: it follows a string of late-stage study setbacks in September that drew close scrutiny of Narasimhan’s dealmaking strategy, and the new targets are meant to shore up confidence in Novartis’s plans beyond 2030.

The commercial momentum behind the raised targets is real, at least on recent numbers. The management presentation put annualized third-quarter sales at $5.9 billion for Kesimpta (up 22% in constant currencies), $2.4 billion for Scemblix (up 67%) and $2.0 billion for Leqvio (up 63%), Securities.io reported.

Reuters adds that Rhapsido and Kisqali are each expected to reach peak annual sales of $8 billion and $10 billion respectively.

Dow Jones Newswires framed it as steady growth “citing momentum from drugs already in the market and upcoming launches,” while Reuters led with the narrowing itself — the lower end of the prior range.

35 or more readouts back the years after 2031

To sustain growth after 2031, Novartis points to 35 or more potentially submission-enabling readouts through 2031 and a pipeline of more than 30 potential high-value assets: over 20 in registration, Phase III or Phase II, and 10 or more in or entering Phase I. Ten late-stage programs carry multi-billion-dollar peak sales guidance, the company said.

The assets highlighted in London span four therapeutic areas: abelacimab for stroke prevention in atrial fibrillation, QCZ484 for hypertension and farabursen for autosomal dominant polycystic kidney disease in cardiovascular-renal-metabolic; Rhapsido in food allergy, ianalumab in lupus and GIA632 in vitiligo in immunology; del-brax, del-zota and votoplam in neuromuscular disease; and pelabresib, 225Ac-PSMA-617 in prostate cancer and a breast cancer portfolio in oncology.

Concrete near-term tests are scheduled for 2027: expected readouts for abelacimab, ianalumab across lupus nephritis, systemic lupus erythematosus and systemic sclerosis, a every-two-month Kesimpta dosing regimen, and zigakibart in IgA nephropathy, according to the presentation. The company also cited internal productivity gains: 25 internally originated projects entering lead optimization in 2025, 25% more than in 2022, with median lead-optimization time down to 2.2 years in 2023–2025, a year faster than in 2020–2022.

2026 comes before any of that

For 2026, the company expects sales to grow at a low-single-digit pace. Core operating income is projected to be anywhere from flat versus the previous year to growing at a low-single-digit rate, Securities.io reported.

Narasimhan, who presented the strategy in London alongside senior leaders with a live webcast and open Q&A, told investors the higher peak sales guidance underpins the 2031 outlook: “The strength of our in-market portfolio is reflected in higher peak sales guidance for Rhapsido, Kesimpta, Scemblix and Leqvio, which together with our other priority brands underpin our expectation of a +5% cc sales CAGR through 2031.”

Whether that confidence holds now rests on the 2027 readouts — and on whether the raised targets for Kesimpta, Scemblix and Leqvio are reached before Cosentyx’s own expiry clock runs down. Neither the company nor its executives have said what happens to the 2031 target if they are not.

Photo of author

Economy Desk

Economy Desk at Archyde.

Wyoming Students Show Gains in Math, English, Science as Enrollment Falls 4,500 Since 2019

Trump Praises Xi Ties, Jokes With Putin At APEC